Wu Lesley, Real Raquel, Martinez Alejandro, Chia Ruth, Lawton Michael A, Shoai Maryam, Bresner Catherine, Hubbard Leon, Blauwendraat Cornelis, Singleton Andrew B, Ryten Mina, Scholz Sonja W, Traynor Bryan J, Williams Nigel, Hu Michele T M, Ben-Shlomo Yoav, Grosset Donald G, Hardy John, Morris Huw R
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
UCL Movement Disorders Centre, University College London, London WC1N 3BG, UK.
medRxiv. 2023 Oct 27:2023.10.17.23297157. doi: 10.1101/2023.10.17.23297157.
Up to 80% of Parkinson's disease patients develop dementia, but time to dementia varies widely from motor symptom onset. Dementia with Lewy bodies presents with clinical features similar to Parkinson's disease dementia, but cognitive impairment precedes or coincides with motor onset. It remains controversial whether dementia with Lewy bodies and Parkinson's disease dementia are distinct conditions or represent part of a disease spectrum. The biological mechanisms underlying disease heterogeneity, in particular the development of dementia, remain poorly understood, but will likely be key to understanding disease pathways and ultimately therapy development. Previous genome-wide association studies in Parkinson's disease and dementia with Lewy bodies/Parkinson's disease dementia have identified risk loci differentiating patients from controls. We collated data for 7,804 patients of European ancestry from Tracking Parkinson's (PRoBaND), The Oxford Discovery Cohort, and AMP-PD. We conducted a discrete phenotype genome-wide association studies comparing Lewy body diseases with and without dementia to decode disease heterogeneity by investigating the genetic drivers of dementia in Lewy body diseases. We found that risk alleles rs429358 tagging and rs7668531 near the and SNCA-AS1 genes, increase the odds of developing dementia and that an intronic variant rs17442721 tagging G2019S, on chromosome 12 is protective against dementia. These results should be validated in autopsy confirmed cases in future studies.
高达80%的帕金森病患者会发展为痴呆,但从运动症状出现到痴呆发生的时间差异很大。路易体痴呆的临床特征与帕金森病痴呆相似,但认知障碍先于运动症状出现或与之同时发生。路易体痴呆和帕金森病痴呆是不同的疾病还是疾病谱系的一部分,仍存在争议。疾病异质性的生物学机制,尤其是痴呆的发展,仍知之甚少,但可能是理解疾病途径以及最终开发治疗方法的关键。先前针对帕金森病和路易体痴呆/帕金森病痴呆的全基因组关联研究已经确定了区分患者与对照的风险位点。我们整理了来自帕金森病追踪研究(PRoBaND)、牛津发现队列和AMP-PD的7804名欧洲血统患者的数据。我们进行了一项离散表型全基因组关联研究,比较有无痴呆的路易体病,通过研究路易体病中痴呆的遗传驱动因素来解码疾病异质性。我们发现,标记 和SNCA-AS1基因附近的rs429358和rs7668531风险等位基因会增加患痴呆的几率,而标记12号染色体上G2019S的内含子变体rs17442721对痴呆有保护作用。这些结果应在未来研究的尸检确诊病例中得到验证。